Eris to buy Biocon arm’s branded drugs for 1,242 crore – Times of India

by The Technical Blogs


NEW DELHI: Biocon is selling branded formulations of its subsidiary Biocon Biologics to Eris Lifesciences for Rs 1,242 crore. The deal will jumpstart Eris’s entry into the over Rs 30,000-crore injectables market in India, and become a leading player in the insulins segment, with acquisition of two major brands – Basalog and Insugen.
It will also mark entry of Eris into oncology and critical care, which are part of the portfolio valued around Rs 350 crore, Krishnakumar Vaidyanathan, executive director and chief operating officer, Eris Lifesciences, said.
Under this deal, Eris has also signed a 10-year supply agreement with Biocon Biologics. The Biocon product range will continue to be manufactured and supplied to Eris for commercialisation in India. The acquisition of Biocon’s insulin brands, valued around Rs 200 crore, will add to Eris’ existing insulin portfolio of Rs 50 crore, Vaidyanathan added. This acquisition also provides immediate synergies with recently acquired Swiss Parenterals business, a company statement says.


Source link

Related Posts

Leave a Comment

Recent Posts

Pigeons swarm Las Vegas neighborhood, nesting at church Study finds adult female elk are badass and can’t be... Vacancy: some more elephants needed in the bush THE TECHNICAL BLOGS

Our Policies

Userful Links

Shop Stores

Copyright @2020  All Right Reserved - Designed and Developed by DSF SEO COMPANY